ABVC BioPharma Inc. (ABVC) shares gained 19.92% in after-hours on Thursday, October 14, 2021, and closed the daily trading at $2.95. Even in regular trading, ABVC’s stock gained 4.68%. Its shares have fallen 38.50% over the last 12 months, and they have moved up 14.42% in the past week. Over the past three months, the stock has lost 50.80%, while over the past six months, it has declined 44.09%.
Let’s discuss its recent news and developments.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
ABVC agreement with Lucidam
On October 12, 2021, ABVC Biopharma, Inc executed a joint venture agreement with Lucidam. The agreement calls for business development collaboration through BioLite Japan, an existing affiliate of ABVC, that seeks to identify early-stage opportunities in drug development, digital health, and medical device technology. ABVC will retain equity ownership in BioLite Japan at 49% (rather than its pre-agreement 50% ownership) and Lucidam will retain equity ownership in BioLite Japan at 51% (rather than its pre-agreement 50% ownership).
ABVC completed site selection
On September 13, 2021, ABVC Biopharma, Inc completed clinical site selection for its ABV-1505 Attention-Deficit Hyperactivity Disorder (ADHD) Phase II Part 2 study. The Phase II, Part 1 study was accepted by the US Food & Drug Administration in October 2020. The Part 2 study of ABV-1505 (ADHD) is a multi-nation multi-site randomized, double-blind, placebo-controlled study involving approximately 100 patients.
ABCV new PCT Filings for MDD and ADHD Treatments
On September 01, 2021, ABVC BioPharma, Inc filed new PCT (Patent Cooperation Treaty) applications in connection with its medicines that treat the major depressive disorder (MDD) and Attention-Deficit Hyperactivity Disorder (ADHD).
ABVC update on Vitargus
On August 26, 2021, ABVC BioPharma, Inc. provided an update regarding recent developments in connection with Vitargus®.
Vitargus is the world’s first bio-degradable vitreous substitute intended to facilitate retina re-attachment surgery. Vitargus can result in eliminating the need for post-surgery patient face-down positioning, as well as significantly greater recovery period patient comfort and visual acuity than currently available products.
Recent financial results
On August 12, 2021, ABVC Biopharma, Inc. announced its unaudited financial results for the three months ended June 30, 2021.
Q2 2021 financial highlights
- The company reported total revenue of $31,441 in Q2 2021 compared to $226,513 in Q2 2020.
- The total operating expenses were $2,066,310 for Q2 2021 compared to $1,416,290 for Q2 2020.
- It suffered a net loss of $2,052,956 for Q2 2021 compared to $2,184,057 in Q2 2020.
Well, as of this writing, there is no recent news or development which could be linked with its gains on Thursday. we hope that it will end the weekly trading session on a positive note.